MX2018013475A - Acido carboxilico para tratar/prevenir congestion nasal. - Google Patents
Acido carboxilico para tratar/prevenir congestion nasal.Info
- Publication number
- MX2018013475A MX2018013475A MX2018013475A MX2018013475A MX2018013475A MX 2018013475 A MX2018013475 A MX 2018013475A MX 2018013475 A MX2018013475 A MX 2018013475A MX 2018013475 A MX2018013475 A MX 2018013475A MX 2018013475 A MX2018013475 A MX 2018013475A
- Authority
- MX
- Mexico
- Prior art keywords
- carboxylic acid
- nasal congestion
- pharmaceutically acceptable
- acceptable salt
- treating
- Prior art date
Links
- 150000001732 carboxylic acid derivatives Chemical class 0.000 title abstract 6
- 206010028735 Nasal congestion Diseases 0.000 title abstract 4
- 150000003839 salts Chemical class 0.000 abstract 5
- 206010061218 Inflammation Diseases 0.000 abstract 3
- 230000004054 inflammatory process Effects 0.000 abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 abstract 3
- 210000002345 respiratory system Anatomy 0.000 abstract 3
- 208000036142 Viral infection Diseases 0.000 abstract 2
- 230000009385 viral infection Effects 0.000 abstract 2
- 208000035473 Communicable disease Diseases 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
- 230000003612 virological effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Otolaryngology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Zoology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
La presente invención se refiere a una composición farmacéutica que comprende un ácido carboxílico o una sal farmacéuticamente aceptable del mismo como ingrediente activo para usar en el tratamiento y/o alivio y/o prevención de una congestión nasal, una enfermedad infecciosa viral del tracto respiratorio o una inflamación de la garganta. Además, la presente invención se refiere a un método para tratar y/o aliviar y/o prevenir congestión nasal, infecciones virales del tracto respiratorio y/o inflamación de la garganta en un paciente, que comprende administrar una cantidad efectiva de un ácido carboxílico o una sal farmacéuticamente aceptable del mismo o una composición farmacéutica que comprende un ácido carboxílico o una sal farmacéuticamente aceptable del mismo a un paciente que lo necesita. Además, la presente invención se refiere a un método para aliviar los síntomas asociados con congestión nasal, infecciones virales del tracto respiratorio y/o inflamación de la garganta que comprende administrar una cantidad efectiva de un ácido carboxílico o una sal farmacéuticamente aceptable del mismo o una composición farmacéutica que comprende un ácido carboxílico o una sal farmacéuticamente aceptable del mismo a un paciente que lo necesita.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16169882 | 2016-05-17 | ||
| PCT/EP2017/061832 WO2017198702A1 (en) | 2016-05-17 | 2017-05-17 | Carboxylic acid for treating/preventing nasal congestion |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2018013475A true MX2018013475A (es) | 2019-08-12 |
Family
ID=56014856
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018013475A MX2018013475A (es) | 2016-05-17 | 2017-05-17 | Acido carboxilico para tratar/prevenir congestion nasal. |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20200000751A1 (es) |
| EP (1) | EP3458043A1 (es) |
| JP (1) | JP6975473B2 (es) |
| KR (1) | KR102430892B1 (es) |
| CN (1) | CN109152754A (es) |
| AU (1) | AU2017266726A1 (es) |
| BR (1) | BR112018072177A2 (es) |
| CA (1) | CA3020485A1 (es) |
| CL (1) | CL2018003270A1 (es) |
| MX (1) | MX2018013475A (es) |
| RU (1) | RU2018143564A (es) |
| SG (2) | SG11201808322PA (es) |
| WO (1) | WO2017198702A1 (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11948678B2 (en) * | 2009-10-14 | 2024-04-02 | Trice Imaging, Inc. | Systems and devices for encrypting, converting and interacting with medical images |
| US11206245B2 (en) * | 2009-10-14 | 2021-12-21 | Trice Imaging, Inc. | Systems and devices for encrypting, converting and interacting with medical images |
| GB202004690D0 (en) * | 2020-03-31 | 2020-05-13 | Edinburgh Napier Univ | Composition for enhancing immune response of cells |
| US12414928B2 (en) | 2021-05-14 | 2025-09-16 | Rene Dumalaog Javier | Viral inactivation spray and gargling formulation |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6063363A (en) * | 1997-05-27 | 2000-05-16 | Goodwin; Gary J | Treatment for upper respiratory tract infections with potassium salts |
| WO1999032125A1 (en) * | 1997-12-23 | 1999-07-01 | Schering Corporation | Composition for treating respiratory and skin diseases, comprising at least one leukotriene antagonist and at least one antihistamine |
| US8912174B2 (en) * | 2003-04-16 | 2014-12-16 | Mylan Pharmaceuticals Inc. | Formulations and methods for treating rhinosinusitis |
| DE10337186A1 (de) * | 2003-08-13 | 2005-03-17 | Merck Patent Gmbh | Wässrige Wirkstoff-Lösung |
| CN1852708B (zh) * | 2003-09-19 | 2010-09-22 | 大塚制药株式会社 | 人β防御素分泌促进剂 |
| US20070256812A1 (en) * | 2006-04-19 | 2007-11-08 | Wen-Chen Wei | Multidirectional heat dissipating structure |
| US20070286812A1 (en) * | 2006-06-09 | 2007-12-13 | Toutounghi Camille | Nasal formulation |
| CA2886270C (en) * | 2012-10-03 | 2020-04-07 | Proponent Biotech Gmbh | Esters of short chains fatty acids for use in the treatment of immunogenic disorders |
-
2017
- 2017-05-17 SG SG11201808322PA patent/SG11201808322PA/en unknown
- 2017-05-17 CN CN201780029992.2A patent/CN109152754A/zh active Pending
- 2017-05-17 BR BR112018072177-8A patent/BR112018072177A2/pt not_active IP Right Cessation
- 2017-05-17 EP EP17723139.6A patent/EP3458043A1/en not_active Withdrawn
- 2017-05-17 US US16/097,784 patent/US20200000751A1/en not_active Abandoned
- 2017-05-17 RU RU2018143564A patent/RU2018143564A/ru unknown
- 2017-05-17 SG SG10202006016QA patent/SG10202006016QA/en unknown
- 2017-05-17 WO PCT/EP2017/061832 patent/WO2017198702A1/en not_active Ceased
- 2017-05-17 CA CA3020485A patent/CA3020485A1/en not_active Abandoned
- 2017-05-17 JP JP2019513481A patent/JP6975473B2/ja active Active
- 2017-05-17 MX MX2018013475A patent/MX2018013475A/es unknown
- 2017-05-17 KR KR1020187033155A patent/KR102430892B1/ko active Active
- 2017-05-17 AU AU2017266726A patent/AU2017266726A1/en not_active Abandoned
-
2018
- 2018-11-16 CL CL2018003270A patent/CL2018003270A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20190009294A (ko) | 2019-01-28 |
| US20200000751A1 (en) | 2020-01-02 |
| WO2017198702A1 (en) | 2017-11-23 |
| JP6975473B2 (ja) | 2021-12-01 |
| CA3020485A1 (en) | 2017-11-23 |
| BR112018072177A2 (pt) | 2019-02-12 |
| CN109152754A (zh) | 2019-01-04 |
| JP2019516797A (ja) | 2019-06-20 |
| RU2018143564A (ru) | 2020-06-17 |
| RU2018143564A3 (es) | 2020-07-23 |
| KR102430892B1 (ko) | 2022-08-09 |
| SG10202006016QA (en) | 2020-07-29 |
| CL2018003270A1 (es) | 2019-02-22 |
| EP3458043A1 (en) | 2019-03-27 |
| AU2017266726A1 (en) | 2018-10-11 |
| SG11201808322PA (en) | 2018-10-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010132695A5 (es) | ||
| HK1221646A1 (zh) | 高剂量普利多匹定用於治疗亨廷顿舞蹈症的用途 | |
| MX393855B (es) | Terapia de combinación que comprende un inhibidor de raf y trametinib | |
| MY196599A (en) | Pharmaceutical compositons comprising n-(3,5-dimethoxyphenyl)-n'-(1-methylethyl)-n-[3-(1-methyl-1h-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine | |
| BR112015029512A2 (pt) | derivados de pirazolopirrolidina e seu uso no tratamento de doenças | |
| EA201270221A1 (ru) | Лечение болезни крона с применением лаквинимода | |
| EA033113B1 (ru) | Способы лечения аутоиммунных, респираторных и воспалительных расстройств ингаляцией n-оксида рофлумиласта | |
| NZ714963A (en) | Compositions and methods for treating anemia | |
| WO2015085143A3 (en) | Therapeutic agents for skin diseases and conditions | |
| JP2015534562A5 (es) | ||
| MD4369B1 (ro) | Utilizarea glicopirolatului pentru tratarea tahicardiei, doză unică, dispozitiv de administrare, metodă de tratament şi profilaxie a tahicardiei | |
| EA201491479A1 (ru) | Производные лупановых тритерпеноидов и их фармацевтическое применение | |
| TN2012000566A1 (en) | Dry powder formulation comprising an antimuscarinic drug | |
| MX377175B (es) | Solucion para inhalacion de tiotropio, administrada en forma nebulizada y el uso de la misma para tratar enfermedad pulmonar obstructiva crónica (epoc). | |
| RU2014141893A (ru) | Применение производной пиразола в лечении острых приступов хронической обструктивной болезни легких | |
| MX2018013475A (es) | Acido carboxilico para tratar/prevenir congestion nasal. | |
| EA201591415A1 (ru) | Фармацевтические композиции, включающие многокомпонентные кристаллические частицы, подходящие для применения в ингаляционной терапии | |
| PH12015502274A1 (en) | Lozenge for treating a sore throat, hoarseness, and associated dry cough and for treating inflammatory diseases of the oral cavity and of the pharynx | |
| EA201201393A1 (ru) | Ингалятор, разработанный для доставки лекарственного средства в виде сухого порошка | |
| MX2018005298A (es) | Regimen de dosificacion para un inhibidor de fosfatidilinositol 3-quinasa. | |
| MX384760B (es) | Combinación farmacéutica sinérgica del enantiómero activo s-ketorolaco y gabapentina para el tratamiento del dolor neuropático. | |
| MX373699B (es) | Composicion farmaceutica que contiene budesonida y formoterol. | |
| WO2013153349A3 (en) | Pharmaceutical composition comprising arformoterol and fluticasone furoate | |
| MX2015009681A (es) | Un medicamento combinado que comprende finilefrina y paracetamol. | |
| WO2013181217A3 (en) | Novel compounds and compositions for treatment of breathing control disorders or diseases |